Table 4.
Demographic and baseline characteristics of the two patient groups (N = 460)
| Characteristics | Overall | Low ALI | High ALI | P value |
|---|---|---|---|---|
| (N = 460) | (N = 230) | (N = 230) | ||
| Gender | 0.388 | |||
| Female | 114(24.8) | 53(23) | 61(26.5) | |
| Age ≥ 65 years | 161(35) | 77(33.5) | 84(36.5) | 0.494 |
| ALI | 39.76(26.84–57.44) | 26.88(19.78–32.35) | 57.39(49.02–73.74) | < 0.001 |
| BMI, kg/m2 | 21.9(19.59–24.34) | 20.96(19–23.04) | 22.71(20.76–25.07) | < 0.001 |
| Albumin, g/l | 38.51 ± 4.6 | 37.14 ± 4.83 | 39.89 ± 3.91 | < 0.001 |
| NLR | 2.12(1.51–2.92) | 2.91(2.38–3.83) | 1.52(1.25–1.88) | < 0.001 |
| TNM stage | 0.797 | |||
| I | 102(22.2) | 48(20.9) | 54(23.5) | |
| II | 53(11.5) | 27(11.7) | 26(11.3) | |
| III | 305(66.3) | 155(67.4) | 150(65.2) | |
| Chemotherapy | 0.548 | |||
| yes | 314(68.3) | 160(69.6) | 154(67) | |
| no | 146(31.7) | 70(30.4) | 76(33) | |
| Histology | 0.474 | |||
| differentiated | 135(29.3) | 71(30.9) | 64(27.8) | |
| undifferentiated | 325(70.7) | 159(69.1) | 166(72.2) | |
| Tumor location | 0.757 | |||
| proximal stomach | 121(26.3) | 64(27.8) | 57(24.8) | |
| distal stomach | 260(56.5) | 127(55.2) | 133(57.8) | |
| total stomach | 79(17.2) | 39(17) | 40(17.4) | |
| OS, month | 39(25–61) | 38(20.75–58.25) | 41(30–64) | 0.044 |
| DFS, month | 39(24–61) | 38(19–58) | 40(28.75–64) | 0.027 |
| LPR | 0.08(0–0.31) | 0.075(0–0.313) | 0.09(0–0.31) | 0.712 |
| Tumor size, cm | 4(2.8–6) | 5(3–6.25) | 3.5(2.5–5) | < 0.001 |
Propensity score-matched data adjusted for age, sex, tumor location, tumor differentiation, TNM stage, and postoperative chemotherapy. ALI Advanced lung cancer inflammation index, BMI Body mass index, NLR Neutrophil–lymphocyte ratio, TNM Tumor-node-metastasis, OS Overall survival, DFS Disease-free survival, LPR Lymph node positive rate on biopsy